{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:00:12Z","timestamp":1793289612293,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019418","name":"NIHR Maudsley Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jtho.2022.07.1148","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T12:01:46Z","timestamp":1660046506000},"page":"1415-1427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"title":["Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial"],"prefix":"10.1016","volume":"17","author":[{"given":"Marina C.","family":"Garassino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Reinmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cove-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Mansy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Migliorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Delmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Garcia","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Enrique","family":"Chara Velarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes","family":"Bernabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio Diaz","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Trunova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayhan","family":"Foroutanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Faivre-Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2022.07.1148_bib1","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2022.07.1148_bib2","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2022.07.1148_bib3","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.21.02528","article-title":"Management of stage III non-small-cell lung cancer ASCO guideline","volume":"40","author":"Daly","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib4","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Electronic address: clinicalguidelines@esmo.org. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.annonc.2019.10.026","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS","volume":"31","author":"Park","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib6","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib7","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S1470-2045(19)30519-4","article-title":"Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study","volume":"20","author":"Hui","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib8","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.1999.17.9.2692","article-title":"Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer","volume":"17","author":"Furuse","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib9","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Auperin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib10","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/ijc.25087","article-title":"Chemo-radiotherapy for advanced non-small cell lung cancer: concurrent or sequential? It\u2019s no longer the question: a systematic review","volume":"127","author":"Liang","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2022.07.1148_bib11","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2022.07.1148_bib12","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2016.07.025","article-title":"Stage III non-small cell lung cancer in the elderly: patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice","volume":"121","author":"Driessen","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib14","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.clon.2017.07.012","article-title":"Treatment variation of sequential versus concurrent chemoradiotherapy in stage III non-small cell lung cancer patients in the Netherlands and Belgium","volume":"29","author":"Walraven","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.jtho.2022.07.1148_bib15","doi-asserted-by":"crossref","first-page":"S656","DOI":"10.1016\/j.jtho.2018.08.1037","article-title":"P1.17-04 curative intent treatment for stage III NSCLC in England","volume":"13","author":"Harden","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib16","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.3747\/co.27.6241","article-title":"Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec","volume":"27","author":"Agulnik","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib17","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.3747\/co.27.6047","article-title":"Retrospective cohort study of unresectable stage III non-small-cell lung cancer in Canada","volume":"27","author":"Seung","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib18","article-title":"A\u00a0real-world, multicenter, observational retrospective study of durvalumab after concomitant or sequential chemoradiation for unresectable stage III non-small cell lung cancer","volume":"11","author":"Bruni","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib19","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1186\/s12885-021-08577-y","article-title":"Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer","volume":"21","author":"Hung","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2022.07.1148_bib20","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jtho.2021.05.003","article-title":"Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC: results of KINDLE, a multicountry observational study","volume":"16","author":"Jazieh","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/annonc\/mdn559","article-title":"Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study","volume":"20","author":"De Ruysscher","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","article-title":"The Eighth edition lung cancer stage classification","volume":"151","author":"Detterbeck","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2022.07.1148_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1183\/09031936.00184308","article-title":"ERS\/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)","volume":"34","author":"Brunelli","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2022.07.1148_bib26","doi-asserted-by":"crossref","first-page":"v461","DOI":"10.1093\/annonc\/mdx380.002","article-title":"Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)","volume":"28","author":"Spigel","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib27","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1200\/JCO.20.00131","article-title":"Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non\u2013small-cell lung cancer: CheckMate 153","volume":"38","author":"Waterhouse","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2022.07.1148_bib28","doi-asserted-by":"crossref","first-page":"S370","DOI":"10.1016\/j.jtho.2018.08.350","article-title":"MA05.02 PACIFIC subgroup analysis: pneumonitis in stage III, unresectable NSCLC patients treated with durvalumab vs. placebo after CRT","volume":"13","author":"Vansteenkiste","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib29","doi-asserted-by":"crossref","first-page":"v592","DOI":"10.1093\/annonc\/mdz259.002","article-title":"Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)","volume":"30","author":"Vansteenkiste","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2022.07.1148_bib30","doi-asserted-by":"crossref","first-page":"S939","DOI":"10.1016\/j.annonc.2021.08.1775","article-title":"1171MO PACIFIC-R real-world study: treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy","volume":"32","author":"Girard","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib31","doi-asserted-by":"crossref","first-page":"ix113","DOI":"10.1093\/annonc\/mdz438.021","article-title":"PACIFIC-5: phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC","volume":"30","author":"Wu","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10147-020-01666-1","article-title":"Rationale of combination of anti-PD-1\/PD-L1 antibody therapy and radiotherapy for cancer treatment","volume":"25","author":"Sato","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib33","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2022.07.1148_bib34","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-16-1673","article-title":"Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade","volume":"23","author":"Dovedi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2022.07.1148_bib35","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtho.2022.07.1148_bib36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/annonc\/mdx790","article-title":"Radiotherapy and anti-PD-1\/PD-L1 combinations in lung cancer: building better translational research platforms","volume":"29","author":"Kordbacheh","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2020.11.024","article-title":"Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable stage III NSCLC (PACIFIC)","volume":"151","author":"Faivre-Finn","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2022.07.1148_bib38","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.6004\/jnccn.2014.0098","article-title":"Management of patients with lung cancer and poor performance status","volume":"12","author":"Gajra","year":"2014","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jtho.2022.07.1148_bib39","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1200\/OP.21.00397","article-title":"Immunotherapy in patients with poor performance status: the jury is still out on this special population","volume":"17","author":"Khaki","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jtho.2022.07.1148_bib40","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1097\/JTO.0b013e318267d032","article-title":"Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003","volume":"7","author":"Morgensztern","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib41","first-page":"144","article-title":"Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation","volume":"46","author":"Kim","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.07.1148_bib43","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3390\/cancers10070222","article-title":"Radiation pneumonitis: old problem, new tricks","volume":"10","author":"Jain","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2022.07.1148_bib44","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1002\/cam4.3093","article-title":"Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin\/docetaxel for non-small cell lung cancer: analysis of dose-volume parameters","volume":"9","author":"Katsui","year":"2020","journal-title":"Cancer Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086422015003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086422015003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:50:24Z","timestamp":1761562224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086422015003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1556086422015003"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2022.07.1148","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2022.07.1148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}